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Background: According to the literature, low serum testosterone levels are associated with diabetes mellitus. No or minimal data 
exist for its prevalence or predictors in South Africa.
Design: This was a cross-sectional study.
Setting: The setting was an academic centre, i.e. the University of Pretoria and Steve Biko Academic Hospital Diabetes Clinic.
Subjects: A total of 150 consecutive male patients aged 50 years and older with diabetes mellitus were selected using conveni-
ence sampling.
Outcome measures: The patients were evaluated for diabetes control and complications, and for hypogonadism symptoms. 
Early-morning serum testosterone levels were determined.
Results: The prevalence of androgen deficiency symptoms was 94.7%. Some 50% of the men had low total testosterone levels. 
Using multivariate logistic regression, the significant factors associated with low total testosterone were waist circumference and 
known cardiovascular disease. The prevalence of symptoms of androgen deficiency was very high; 94.7% of the patients reported a 
significant number of symptoms listed on the Androgen Deficiency in the Aging Male questionnaire.
Conclusion: This study confirms the high prevalence of low testosterone levels in diabetic male patients in a tertiary setting. 
Universal screening remains controversial owing to uncertainty regarding the risks and benefits of testosterone therapy in this 
population group. Predictors of low testosterone levels were identified.
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Introduction
Male hypogonadism is a clinical condition, consisting of both the 
symptoms and biochemical evidence of a low testosterone level. A 
condition called testosterone or androgen deficiency syndrome 
has been described with advancing age.1,2 The prevalence of male 
hypogonadism varies in the different populations and age groups 
studied. Its prevalence increases in male patients with diabetes 
mellitus, but minimal data are available on South African men with 
this condition.
Men with obesity, metabolic syndrome and type 2 diabetes often 
have low total and free testosterone, and low sex hormone binding 
globulin.3−6 Low testosterone levels in men in the Rancho Bernardo 
study were predictive of insulin resistance and incident type 2 
diabetes in older adults.7 The nature of the relationship between 
type 2 diabetes mellitus and low testosterone levels remains 
unclear. A relationship between low serum testosterone levels and 
obesity, and the fact that this relationship predisposes these men 
to develop the metabolic syndrome, insulin resistance and type 2 
diabetes, has been demonstrated in several studies, including the 
Massachusetts Male Aging Study.1,3,8−10 Low testosterone levels 
could also be a consequence of diabetes mellitus, but even young 
men with type 2 diabetes and newly diagnosed type 2 diabetic 
patients have a high prevalence of hypogonadotropic 
hypogonadism.11 A low testosterone level could also just be a 
biomarker that coexists with diabetes because of mutual risk 
factors, such as obesity and advancing age.3,5
It was found in a previous study that at least 25% of men with type 
2 diabetes had subnormal testosterone levels, with inappropriately 
low luteinising hormone (LH) and follicle-stimulating hormone 
(FSH) concentrations, indicative of hypogonadotropic 
hypogonadism.11 A small percentage had subnormal testosterone 
levels with elevated LH and FSH concentrations, implying primary 
hypogonadism. Hypogonadotropic hypogonadism is the most 
common picture found in hypogonadal diabetic men.11,12 One 
study found a prevalence of 33% of low free testosterone in type 2 
diabetic men.13
Obesity can play a role in the pathophysiology of both 
hypogonadism and type 2 diabetes. Obesity is associated with 
hypogonadotropic hypogonadism. Thus, it is possible that this 
precedes diabetes.11,14 Obesity is a proinflammatory state.3 Visceral 
fat produces inflammatory cytokines, adipokines and other 
proinflammatory factors, such as interleukin (IL)-6, IL-1β, tumour 
necrosis factor-alpha, plasminogen activator inhibitor-1, 
angiotensinogen, vascular endothelial growth factor and serum 
amyloid A. Obesity also leads to an increased release of oestrogen 
and free fatty acid. These factors can all potentially contribute to 
the suppression of the hypothalamus–pituitary–gonadal axis, 
and can lead to androgen deficiency.15
There might also be a direct effect of testosterone on insulin 
sensitivity, with testosterone deficiency leading to insulin 
resistance.1,9,16 Interactions between visceral adiposity and low 
testosterone levels through proinflammatory factors can result 
in insulin resistance and vascular endothelial dysfunction.3 These 
can be potential causal factors for increased erectile dysfunction 
and cardiovascular disease. Leptin resistance at the hypothalamic-
pituitary and testicular levels can also contribute to lowered 
testosterone levels.17
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The complications of hypogonadism are numerous and varied, 
from impairment of quality of life to effects on mortality. Type 2 
diabetic men with low testosterone levels have been found to 
have a high prevalence of symptoms of hypogonadism, such as 
erectile dysfunction, low libido and fatigability.14,18
Method
Setting
The study was performed in an academic centre, i.e. Steve Biko 
Academic Hospital Diabetes Clinic, University of Pretoria. This is a 
tertiary diabetes clinic in a state hospital. The University of Preto-
ria Ethics Committee approved the study (213/2011).
Subject selection
A total of 150 consecutive male patients aged 50 years and older 
with diabetes mellitus were selected using convenience sampling.
Research procedures
Information was obtained from the patients themselves, their 
hospital and clinic files, the hospital laboratory system, and from 
a questionnaire that the patients completed.
The demographic variables, such as the age, race, smoking histo-
ry and employment status, of the patients were recorded.
Clinical variables, including the type of diabetes mellitus and the 
time since diagnosis, as well as the presence of hypertension and 
the time since diagnosis, were recorded. A previous history of a 
stroke, myocardial infarction, amputation, foot ulceration, cataracts, 
revascularisation, nephropathy or laser therapy of the eyes was 
obtained. Blood pressure was taken and averaged with the last 
recorded value, body mass index (BMI) was calculated and waist 
circumference (WC) measured. Current medications that the 
patients were using were recorded.
Patients completed the Androgen Deficiency in the Aging Male 
(ADAM) questionnaire.19,20 The ADAM questionnaire consists of 10 
questions that evaluate the kind and severity of low testosterone 
symptoms. A diagnosis of ADAM was suspected if a ‘yes’ answer 
was provided to questions 1 and 7, or to any other three questions. 
Patients were categorised as being ADAM-positive or ADAM-
negative.
A peripheral neuropathy questionnaire (modified Neuropathy 
Symptom Score) was also completed.21 This questionnaire consists of 
five questions on the symptoms of peripheral neuropathy. Patients 
could answer ‘no’, ‘yes’, and grade it by answering ‘worse at night’.
The World Health Organization’s Rose Angina Questionnaire can be 
used to diagnose intermittent claudication.22 It consists of nine 
questions, and intermittent claudication was diagnosed or ruled out 
based on the patient’s choice out of two possible answers. The 
questionnaires were chosen for their simplicity and brevity, although 
none of them were validated in a South African population.
Laboratory measurements
Biochemical variables included routine tests, such as a serum 
creatinine, serum low-density lipoprotein (LDL) value and 
haemoglobin A1c (HbA1c). Urine for an albumin/creatinine ratio was 
collected as a random spot urine specimen after exclusion of a 
possible urinary tract infection using a urine dipstick. Total 
testosterone non-routine tests were requested. Blood was collected 
in the fasting state between 7h:00 am and 10:00 am in clotting 
tubes following venepuncture, and was immediately refrigerated. 
It was transported to the laboratory (Dr WJH Vermaak Inc.) for 
analysis on the same day. The Roche® total testosterone assay was 
used on the Cobas® 6000 analyser (Roche Diagnostics, Rotkreuz, 
Switzerland). The laboratory-specific reference range of total 
testosterone for males aged 50 years and older is 9.9–27.8 nmol/l.
Data analysis
Data were analysed with Stata® 12 (Stata Corp, College Station, TX, 
USA). Exposure between cases and non-cases was compared using 
appropriate tests for continuous and categorical data. Logistic 
regression was utilised to determine predictors of outcome with 
tests of calibration and validation, as required. Logistic regression 
was performed to evaluate the relationship between demographic 
variables, clinical variables, biochemical variables, the different 
health-related questionnaires, and the outcome (low or normal 
testosterone levels), to determine which variables to use in the 
multivariate model. The outcome variable ‘testosterone’ was 
modelled as a dichotomous variable (low or normal). This was 
carried out for simplicity.
Variables with a p-value  <  0.25 were entered into a multivariate 
model with manual backward elimination, based on the p-values in 
the model. Variables were dropped if the p-value was nonsignificant 
(< 0.05). Sensitivity, specificity, and the positive and negative 
predictive values were calculated. To determine the calibration of 
the final model, receiver-operating characteristic (ROC) analysis 
was performed with calculation of the c-statistic. Tenfold cross-
validation of the area under the ROC curve was used for validation.
Results
Table 1 shows patients’ clinical and biochemical demographic 
characteristics at baseline. The mean was reported for data that 
were normally distributed, with the standard deviation (SD). A 
median was reported for data with a skew distribution, with an 
interquartile range (IQR) from the 25th–75th percentile.
In all, 91% of the patients had type 2 diabetes mellitus, and the 
mean age was 62 years (SD 7.9 years). Just over half of the patients 
were white (53%) and 30% were black. The mean diabetes 
duration was 15 years (SD 8.7 years). Some 95% of the patients 
had previously been diagnosed with hypertension, but this was 
relatively well controlled with a mean systolic blood pressure of 
134 mmHg (SD 15.5 mmHg) and mean diastolic blood pressure of 
77 mmHg (SD 9.3 mmHg). The patients were obese, with a mean 
BMI of 31 kg/m2 (SD 5.37 kg/m2) and a mean WC of 112 cm (SD 
16.4 cm). Sixty-six per cent of the patients were current (24%) or 
past (42%) smokers (not shown).
The median serum creatinine was 96 μmol/l (IQR 79–133 μmol/l). The 
patients’ diabetes was better controlled than expected, with a 
median HbA1c of 7.9 mmol/mol (IQR 6.8–9.3 mmol/mol). The mean 
LDL was above target at 2.33 mmol/l (SD 0.7 mmol/l), and the median 
triglycerides (TGs) was 1.90  mmol/l (IQR 1.20–2.50  mmol/l). The 
median serum total testosterone was 9.88  nmol/l (IQR 7.04–
14.13 nmol/l).
Forty-one per cent of the patients were known to have cardiovascular 
disease and 6.7% intermittent claudication. Microvascular 
complications were common, with symptoms of peripheral 
neuropathy present in 43% of the study population, microalbuminuria 
in 48% of the patients, and proliferative diabetic retinopathy in 25%. 
Present or past cataracts affected almost 59% of the patients.
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Eighty-five per cent of the patients were on insulin therapy. 
Metformin was prescribed to 64% of them. Statin usage was high 
at 93%, and diuretics were prescribed to 82% of the study 
population. Low serum total testosterone levels were present in 
50% of the patients.
Figure 1 is a scatter plot of the individual total testosterone values.
As demonstrated in Table 2, univariate associations of a low total 
testosterone that were statistically significant (p-value  <  0.05) 
were BMI, WC, known cardiovascular disease and units of insulin 
used per day.
Table 3 shows the statistically significant multivariate associations 
of a low total testosterone, i.e. WC and known ischaemic heart 
disease. The statistically significant multivariate associations were 
used to create a prediction model and ROC curve (Figure 2).
Table 1: Baseline characteristics of the patients (the clinical and biochemical variables)
Variable n (%) Mean (SD) Median (IQR)
Type of diabetes mellitus
Type 1 13 (8.7)








Past or present cardiovascular disease 61 (40.7)
Known to have proliferative diabetic retinopathy 38 (25.3)
Significant peripheral neuropathy present 64 (43.2)
Intermittent claudication (Rose questionnaire)* 10 (6.7)
Present or past cataracts 86 (58.5)
Microalbuminuria present 72 (48.0)
Other
Age (years) 62 (7.9)
Diabetes duration (years) 15 (8.7)
Body mass index (kg/m2) 30.7 (5.37)






Serum creatinine 96 (79–133)
Laboratory tests
HbA1c (mmol/mol) 7.9 (6.8–9.3)
Low-density lipoprotein (mmol/l) 2.33 (0.70)
Serum total testosterone (nmol/l) 9.88 (7.04–14.13)
Low total testosterone (nmol/l) 75 (50.0)
* = World Health Organization’s Rose Angina Questionnaire.
HbA1c = haemboglobin A1c, IQR = interquartile range, SD = standard deviation.






















Figure 1: Scatter plot of the individual total testosterone values.
Note: The horizontal line represents a lower cut-off value of 9.9 nmol/l.
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identified in this study, and were very similar to those reported in 
the literature.3,5,9,12 When statistical measures were considered, 
the prediction model created from the significant multivariate 
associations did not perform well. Only 66% of the participants 
were correctly classified as having low total testosterone levels.
The prevalence of androgen deficiency symptoms was 94.7% 
using the ADAM questionnaire. This was a much higher prevalence 
than that reported in the literature.12 The almost universal presence 
of these symptoms, even in patients with normal testosterone 
levels, made this questionnaire less useful for screening purposes. 
Most of the questions are relatively non-specific regarding 
symptoms, such as a lack of energy, being sad or ill-tempered, or 
experiencing a decreased enjoyment of life, strength or work 
performance. These symptoms can be present in many other 
chronic diseases and, as demonstrated, our population had 
numerous co-morbidities. Some of the questions focused on 
erectile dysfunction. There are multiple other contributing factors 
to this condition in diabetic patients, such as medication, 
neuropathy and vasculopathy.
There were several limitations to the study. It was conducted in a 
tertiary outpatient diabetic clinic, where most of the patients had 
complications of their disease and numerous co-morbid conditions. 
Therefore, the results cannot be generalised to the majority of 
diabetic patients who follow-up at primary healthcare facilities.
Patient selection bias was to some degree minimised, but not 
totally eliminated, by enrolling 150 consecutive patients. For 
example, most rural patients arrived regularly after 10:00 am at 
the clinic, which was too late for them to be included in the study 
since blood tests had to be performed in the morning. A limited 
number of Asian and coloured patients were included, which would 
make the results more difficult to interpret in these population 
groups.
Some of the information was subjectively obtained from patients 
without external collaboration, such as a history of ischaemic 
heart disease. Only proliferative diabetic retinopathy (either 
objectively observed, documented in the ophthalmology notes, 
or a history of laser therapy or haemorrhage provided by the 
patient) was recorded, owing to multiple examiners with different 
levels of expertise.
Table 4 summarises the areas under the ROC curve, before and 
after cross-validation. By using the model to predict low total 
testosterone, the area under the ROC curve was 0.70, i.e. it just 
reached an acceptable discrimination level. The sensitivity was 
67% and the specificity was 65%. The positive predictive value 
was 66%, with a similar negative predictive value.
The prevalence of symptoms of androgen deficiency was very 
high. Ninety-five per cent of the patients reported a significant 
number of symptoms on the ADAM questionnaire.
The sensitivity to identify those with low total testosterone was 
very high at 95%, but the trade-off was a low specificity of 5%. The 
positive and negative predictive values were both 50%, and thus 
not useful.
Discussion
The prevalence of low testosterone levels was higher than those 
reported in the literature.6,11−14 Half of the men had low total 
testosterone levels. This could be because our diabetic population 
had multiple co-morbid diseases and advanced diabetic 
complications, which can all influence testosterone levels, and 
they were older (a mean age of 62 years) than patients in other 
studies. Novel predictors of low testosterone levels could not be 
Table 2: Summary of univariate analysis, showing statistically significant variables with total testosterone
Variable Normal total testosterone Low total testosterone p-value
Body mass index (kg/m2) (mean SD) 29.4 (4.9) 32 (5.5) 0.004
Waist circumference (cm) (mean SD) 108 (14.1) 117 (17.3) < 0.001
Known cardiovascular disease (n, %) 22 (29.3) 39 (52.0) 0.005
Units of insulin per day (mean SD) 50 (42.7) 69 (55.8) 0.022
Note: SD = standard deviation.
Table 3: Statistically significant multivariate associations of a low total testosterone
Multivariate associations
Low total testosterone OR SE 95% CI (lower limit) 95% CI (upper limit) p-value
Waist circumference 1.04 0.01 1.01 1.06 0.003
Ischaemic heart disease 2.18 0.78 1.09 4.39 0.029

















Area under ROC curve = 0.7049
Figure 2: Receiver-operating characteristic curve (a model for low  
total testosterone).
 Note: ROC = receiver operating characteristic.
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testosterone was associated with an increased risk of adverse 
outcomes, such as a stroke, myocardial infarction and death.29−32 
This will need to be confirmed in larger trials. Not many large trials 
have evaluated the longterm potential risks, such as prostate 
cancer and cardiovascular events.6,28,32−34
In conclusion, this study confirmed the high prevalence of low 
testosterone levels in diabetic male patients in a tertiary setting. The 
associations of low testosterone levels were identified. However, 
universal testing remains controversial owing to uncertainty about 
the beneficial and detrimental effects of testosterone therapy in this 
population group. The ADAM questionnaire was not useful in 
identifying subjects with a low testosterone level.
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